[The effect of latanoprost 0.005% on pupillary reaction of the human eye].
OBJECTIVE
Infrared pupillography was performed to investigate the effect of one week topical treatment with the prostaglandin analogue Latanoprost 0.005% on pupillary reflex to light stimuli in glaucomatous human eyes.


METHODS
Infrared pupillography using the compact integrated pupillograph was performed in 20 glaucomatous eyes of 11 patients. After 10 minutes dark adaptation one pupil was stimulated with a blue, yellow and white diode light of 100 ms duration. Measurements of pupil diameter, constriction latency, constriction amplitude and relative constriction amplitude were taken twice for each light source in a time interval of 15 seconds. After a 2 week wash-out period the measurements were performed from 8:00 to 10:00 a.m. before and one week after topical treatment with Latanoprost 0.005% applied as single dose once in the evening.


RESULTS
The measurements after 1 week treatment with Latanoprost showed a significantly smaller pupil diameter for blue (p = 0.044) and white stimulus (p = 0.039) and the latency was significantly reduced (p = 0.029) as well.


CONCLUSIONS
Although the statistical analysis shows some small significant differences in pupil diameter and constriction latency there were no clinical signs of changes in pupillary response due to Latanoprost. The system turned out as easy to use and showed reliable measurements during the study. How far latanoprost may lead to miosis and a decrease of constriction latency has to be investigated in further studies with larger study populations. Other topics concerning drug influence, diurnal rhythm and glaucomatous damage in pupillary light reaction will be investigated in the near future.
Dinslage
S
S
Zentrum für Augenheilkunde, Universität zu Köln. sven.dinslage@uni-koeln.de
Diestelhorst
M
M
Kühner
H
H
Krieglstein
G K
GK
D000959:Antihypertensive Agents / Q000008:administration & dosage*; D003936:Diagnosis, Computer-Assisted / Q000295:instrumentation; D004568:Electrodiagnosis / Q000295:instrumentation; D004867:Equipment Design; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008838:Microcomputers; D009883:Ophthalmic Solutions; D010775:Photic Stimulation; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage*; D012025:Reflex, Pupillary / Q000187:drug effects*
D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost